Bakkt Holdings
BKKT
Bit Origin
BTOG
Intchains Group
ICG
Mawson Infrastructure
MIGI
FRMO CORP
FRMO
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 253.545
- +0.105+0.04%
Close Mar 20 16:00 ET
32.82BMarket Cap-116.31P/E (TTM)
261.900High252.385Low799.08KVolume254.090Open253.440Pre Close205.27MTurnover0.64%Turnover RatioLossP/E (Static)129.46MShares304.39052wk High489.47P/B31.56BFloat Cap141.97552wk Low--Dividend TTM124.46MShs Float304.390Historical High--Div YieldTTM3.75%Amplitude3.650Historical Low256.886Avg Price1Lot Size
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Alnylam Pharmaceuticals Stock Forum
Breakthrough: New FDA-Approved Heart Disease Drug Cuts Death Risk by 36%
Alnylam Crushes Earnings with 33% Revenue Growth, Sets Sights on First Profitable Year
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
No comment yet